New Leukemia Rx Gets FDA Nod
Doctors may now have another tool in their arsenal for the treatment of chronic lymphocytic leukemia (CLL).
FDA Approves New Leukemia Rx
On January 19, 2016, the U.S. Food and Drug Administration approved ofatumumab (Arzerra Injection, Novartis Pharmaceuticals Corporation) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL).
New VTE Guidelines Released
The American College of Chest Physicians (CHEST) issued some new guidelines for the treatment of venous thromboembolism (VTE).
Before Cancer Surgery, Blood Thinners Appeared Safe
Cancer patients have enough to worry about — they shouldn't have to worry about the health effects of medications taken before cancer surgery. And new evidence suggests they may not have to.
Novel Blood Clot Rx Shows Potential
Antiplatelet medications, while highly effective, can put surgical patients at risk of serious bleeding. But a new, safer drug may be on the horizon.
A New Treatment Option for Adult Leukemia
Patients may now have an alternative to chemotherapy as their first line of defense against chronic lymphocytic leukemia (CLL).
New Rx Treats Most Common Inherited Bleeding Disorder
Patients with von Willebrand disease (VWD) lack a protein that's essential for healthy blood clotting. But a newly approved medication could help with that.
FDA Approves New von Willebrand Rx
The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD).
An Antibiotic Benefit for Childhood Leukemia
For kids with acute lymphoblastic leukemia (ALL), bacterial infections can cause dangerous complications. But a new treatment option may be able to help.
Bendeka Gets the Green Light
JERUSALEM & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announce that the U.S. Food and Drug Administration (FDA) has approved BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine.